04.05.2011 • NewsBilanzSolutiaSolar Power

Solutia Q1 Profit Beats Street, Sales Miss

Specialty chemicals maker Solutia posted a better-than-expected quarterly profit, helped largely by sales of parts for solar panels, window glass and automotive tires. The company makes niche products, including screen parts for Amazon.com's Kindle, that customers are willing to pay a premium for as the economy recovers.

Solutia said its first-quarter net income was $65 million, or 54 cents per share, compared with a net loss of $58 million, or a loss of 49 cents per share, a year ago.

Excluding the cost of relocating its European headquarters, the gain on the sale of a rubber chemicals operation and other one-time items, Solutia said it earned 50 cents per share. By that measure, analysts, on average, had expected earnings of 46 cents per share, according to Thomson Reuters I/B/E/S.

Revenue rose 14% to $509 million, missing the $515.9 million analysts, on average, had expected.

Demand for solar panel parts and acoustic layers for window glass helped lift sales at the company's advanced interlayers unit by 15% to $213 million, Solutia said.

The technical specialties unit, which makes insoluble sulfur for tires, rose 7% to $220 million. For the full year, Solutia said it expects adjusted earnings of $2.10 to $2.25 per share. Analysts, on average, expect $2.18 per share.

Solutia was spun off from Monsanto in 1997.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read